Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Sareum Holdings shares spike ahead of US poster presentations

Currently, SRA737 is in phase I/II clinical trials as a single therapy to treat certain stress-driven cancers
Sareum Holdings shares spike ahead of US poster presentations
The writing's on the wall: Delegates at a cancer conference will be told SRA737 “synergises” with PARP inhibitor, niraparib

Shares in Sareum Holdings PLC (LON:SAR) rose 9% ahead of poster presentations at a key cancer conference by partner Sierra Oncology.

Sierra is the licence holder for Sareum-developed SRA737. The posters will outline pre-clinical results from its research, including late breaking data. They will be on show at the American Association of Cancer Research annual meeting in Chicago.

WATCH: Sareum Holdings PLC heartened by Sierra Oncology progress

Poster one will reveal that checkpoint kinase-1 inhibitor SRA737 is active in both PARP inhibitor-resistant and CCNE1 high-grade serous ovarian cancers.

Synergies with PARP inhibitor

Poster two will inform delegates the drug “synergises” with PARP inhibitor, niraparib, to kill carcinoma cells via multiple cell death pathways.

PARP inhibitors prevent cancer cells from repairing themselves. PARP stands for poly-ADP ribose polymerase and is found in human cells.

Currently, SRA737 is in Phase I/II clinical trials as a single therapy to treat certain stress-driven cancers.

Sierra is also preparing to test its potential in combination with niraparib to tackle hard-to-treat forms of prostate cancer. 

The shares rose 0.045p to 0.9p.

View full SAR profile View Profile

Sareum Holdings Plc Timeline

Related Articles

September 28 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing
September 20 2018
Following the disappointment of its DMD treatment over summer, Summit is leveraging its Discuva platform to develop new antibiotics, which doctors are in desperate need of
little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use